While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities going forward.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
pSivida was leading the bulls in Tuesday’s session on positive results from a late stage trial of Medidur.
AVEO Pharmaceuticals was leading the bulls in Monday’s session on news of an exclusive licensing agreement.
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
KemPharm expects to price its 3 million shares around last Thursday's closing price of $18.88, which would value the entire secondary offering at up to more than $65 million.
Intercept Pharmaceuticals announced that the FDA has extended the PDUFA date for its Priority Review of obeticholic acid in primary biliary cholangitis.
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
As quickly as KaloBios Pharmaceuticals shares shot up, they are dropping after its newly named chief executive, Martin Shkreli, was arrested.
All these Cowen picks offer compelling values for 2016, and all have backed up enough in price for investors to get an outstanding entry point.
Advaxis has announced that the FDA has lifted the clinical hold on all of its Investigational New Drug (IND) applications for its three product candidates
Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.
